Moderna, Inc. (MRNA)
A lot of concern around Moderna over next year or so, says Jefferies Michael Yee
Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Moderna (NASDAQ:MRNA ) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Ellie Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Tyler Van Buren - TD Cowen Luca Issi - RBC Capital Courtney Breen - Bernstein Edward Tenthoff - Piper Sandler Jessica Fye - J.P. Morgan Simon Baker - Redburn Atlantic Myles Minter - William Blair Tim Anderson - Bank of America Operator Good day, and thank you for standing by.
Moderna shares rise on quarterly revenue beat despite wider-than-expected loss
Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported a wider-than-expected loss per share of $2.91, compared to estimates of a loss per share of $2.73.
Moderna's Q4 Loss Wider Than Expected
Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.
Moderna has no 'visible path' to profitability, analyst says
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight.
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.
MRNA Reiterates Guidance, Bird Flu Vaccine in Pipeline
Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-19 pandemic.
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.
Moderna beats on revenue but loses more than expected as it scales down manufacturing
Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.
Moderna's wider-than-expected loss and soft guidance weigh on battered stock
COVID-19 vaccine sales topped consensus but RSV sales remain modest
